In a report published Friday, J.P. Morgan reiterated its Overweight rating on Covance (NYSE: CVD ), and raised its price target from $68.00 to $70.00. J.P. Morgan noted, “Given a diversified service offering, increasing geographical footprint, economies of scale, and growing biotechnology and pharmaceutical customer base, which have become increasingly